Key clinical point: “Real-life” data show a benefit of rifaximin on symptoms and complications experienced by patients with symptomatic uncomplicated diverticular disease of the colon.
Major finding: Acute diverticulitis occurred in 9 patients in the rifaximin group (2.6%) and in 21 patients who did not receive rifaximin (4.5%), a difference that reached statistical significance (P = .155).
Study details: A retrospective study of 816 patients with symptomatic uncomplicated diverticular disease.
Disclosures: The researchers reported having no financial disclosures.
REPORTING FROM DDW 2019